Article citationsMore>>

Palmer, L.B., Smaldone, G.C., Chen, J.J., Baram, D., Duan, T., Monteforte, M., Varela, M., Tempone, A.K., O’Riordan, T., Daroowalla, F. and Richman, P. (2008) Aerosolized Antibiotics and Ventilator-Associated Tracheobronchitis in the Intensive Care Unit. Critical Care Medicine, 36, 2008-2013.
http://dx.doi.org/10.1097/CCM.0b013e31817c0f9e

has been cited by the following article:

• TITLE: Natural History, Outcomes and Antibiotic Treatment for Ventilator-Associated Tracheobronchitis in Critical Ill Patients

  AUTHORS: Yuxiu Lei, Jana Hudcova, Jawad Rashid, Akmal Sarwar, Wendy Gillespie, Carol Finn, Marie Goggin, Mohamed B. Omran, Edward Boroda, Donald E. Craven

  KEYWORDS: Ventilator-Associated Tracheobronchitis (VAT) and Pneumonia (VAP), Bacterial Pathogens, Semi-Quantitative Endotracheal Aspirate (SQ-ETA) Cultures, Antibiotic Therapy

  JOURNAL NAME: Modern Research in Inflammation, Vol.5 No.1, February 29, 2016

  ABSTRACT: We assessed incidence and outcomes of patients with ventilator-associated respiratory infections (VARI) due to tracheobronchitis (VAT) and pneumonia (VAP), including length of intensive care unit (ICU) stay and ventilator days. We also examined pathogens, rate of progression from VAT to VAP, and impact of antibiotic therapy for VAT. Data analysis included 234 patients, 100 patients (43%) had at least moderate (+++) bacterial growth in their semi-quantitative endotracheal aspirate (SQ-ETA) cultures. VAT and VAP were each diagnosed in 34 (15%) patients. Staphylococcus aureus was the most common pathogen isolated and had the highest rate of progression from VAT to VAP. Seven (21%) of the 34 patients were diagnosed with VAT that later progressed to VAP in averaged 3 days. Patients diagnosed with VAT had significantly more ventilator days (9 vs 6, p p p